Liraglutide protected chondrocytes from AGE-induced inflammation and cartilage destruction by blocking RAGE signaling, suggesting GLP-1 drugs may have joint-protective benefits for osteoarthritis.
First evidencethat liraglutide protects cartilage from AGE-induced damage, adding joint health to the expanding list of GLP-1 drug benefits
What the researchers found
Liraglutide reduced RAGE expression, suppressed IL-6/IL-12/TNF-α, decreased MMP-1/-3/-13 and ADAMTS-4/-5, preserved aggrecan and collagen II, and reduced chondrocyte apoptosis via GLP-1R activation, with all effects reversed by GLP-1R blockade.
Why it matters
Osteoarthritis affects over 500 million people with no disease-modifying treatment. If liraglutide protects cartilage through RAGE suppression, the millions of people already taking GLP-1 drugs for diabetes may be getting unrecognized joint protection.
The numbers in context
Liraglutide reduced MMP and ADAMTS catabolic enzymes while preserving aggrecan and collagen II anabolic markers in AGE-treated chondrocytes.
How the study worked
In vitro study using rat primary chondrocytes treated with AGEs ± liraglutide ± exendin (GLP-1R blocker). Measured inflammatory cytokines (ELISA), catabolic/anabolic gene expression (RT-PCR), RAGE expression (Western blot), and apoptosis (TUNEL, caspase-3, immunofluorescence).
Who was studied
Chondrocytes treated with AGEs and liraglutide in culture
What this study cannot tell us
In vitro cell culture study — joint cartilage in living organisms is exposed to different mechanical and biological forces. Liraglutide concentrations used may not match what reaches joint tissue from systemic dosing. No animal or human osteoarthritis data. The GLP-1R inhibitor used (exendin) may have partial agonist effects.
How to read the evidence
Preliminary evidence: in vitro cell culture study with clear mechanistic findings through GLP-1R pathway, but no animal or clinical data.
When this study was published
Published in 2024. First study investigating GLP-1 agonists in AGE-induced chondrocyte damage.
The bigger picture
GLP-1 drugs keep revealing unexpected tissue-protective effects. Cartilage protection through AGE/RAGE pathway inhibition adds to the growing list of benefits beyond blood sugar control. Since AGE accumulation is accelerated in diabetes and aging — the same populations taking GLP-1 drugs — this could represent a clinically meaningful secondary benefit.
Questions still open
- Do patients taking GLP-1 drugs show lower rates of osteoarthritis or slower joint degeneration?
- Could local injection of GLP-1 agonists into joints protect cartilage in osteoarthritis patients?
- Is the cartilage-protective effect driven by weight loss, anti-inflammatory effects, or direct GLP-1R activation on chondrocytes?
Common questions
Could GLP-1 drugs help with osteoarthritis?
What are AGEs and how do they damage joints?
Read the original research
Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes.
BMC musculoskeletal disorders, 25(1), 601
Citation
Zhang, Xianyu; Jiang, Jian; Xu, Jiajia; Chen, Jian; Gu, Yuntao; Wu, Guobao. (2024). Liraglutide, a glucagon-like peptide-1 receptor agonist, ameliorates inflammation and apoptosis via inhibition of receptor for advanced glycation end products signaling in AGEs induced chondrocytes.. BMC musculoskeletal disorders, 25(1), 601. https://doi.org/10.1186/s12891-024-07640-6